At a recent symposium hosted by the Hong Kong Society of Haematology (HKSH) that discussed the current and future trends of the management of mantle cell lymphoma (MCL), Professor Simon Rule presented topics related to the trend of MCL management, the prognostic risk factors, and the risk stratifica

The standard treatment for physically fit and young patients with advanced chronic lymphocyticleukemia (CLL) and genetic risk factors is the chemoimmunotherapy (CIT) regimen of fludarabine+ cyclophosphamide + rituximab or bendamustine + rituximab, especially in many Europeancountries, where the continuous treatment with Bruton tyrosine kinase inhibitors (BTKi), such asibrutinib, is approved but not reimbursed.¹ In unfit patients, trials have shown greater improvementsin progression-free survival (PFS) with venetoclax + obinutuzumab as a time-limited therapycompared with chlorambucil + obinutuzumab.¹ Other phase 2 trials also demonstrated remarkableimprovements in the undetectable minimal residual disease (MRD) rates with the triple combinationconsisting of adding BTKi to venetoclax + obinutuzumab.¹

Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by an increased number of circulating clonal B-cells with typical morphology and immunophenotype.¹ Accounting for 25% of all leukemias in adults, CLL is the most common leukemia in the Western world.¹ To address the clinica

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.¹ When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor

Although chronic lymphocytic leukemia (CLL) patients now have a broader selection of treatment options available, therapeutic efficacies of most treatments still largely depend on the patients’ fitness, cytogenetics and previous treatment responses. Some clinically relevant mutations have now been identified to predict

Primary Sjögren’s Syndrome (pSS) is the second most prevalent systemic autoimmune disease characterized by ocular and oral dryness, musculoskeletal pain, profound fatigue, and an increased risk of lymphoma.¹ Although the symptoms are identifiable, pSS remains incurable due to its

Most of the Hodgkin lymphoma (HL) patients respond well to frontline treatment, but such treatments induce unacceptable organ toxicities and immune suppression, which leads to secondary malignancies and cardiac disease.¹ Therefore, increased interest has drawn towards targeted